SpringWorks Q1 OGSIVEO revenue $21M; net loss widens to $87.4M

SpringWorks Therapeutics, Inc.

2024-Q1 EPS reported -$1.18 revenue$21,006,000

OGSIVEO net product revenue $21.0M in first full quarter of U.S. launch.
Net loss $87.4M ($1.18 per share) vs. $73.4M ($1.18 per share) in Q1 2023, driven by higher SG&A and R&D costs.
Cash, equivalents and marketable securities $573.0M as of March 31, 2024.
EMA validated MAA for nirogacestat in desmoid tumors; rolling NDA submission for mirdametinib in NF1-PN initiated.
Phase 2b ReNeu trial results accepted for oral presentation at 2024 ASCO Annual Meeting.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SpringWorks Therapeutics, Inc. reported the quarter ended March 31, 2024 results: revenue $21.0 million, net income $87.4 million, EPS $1.18 per share.

Period: the quarter ended March 31, 2024
Revenue: $21.0 million
Net income: $87.4 million
EPS: $1.18 per share
Result: reported results

Exact text from the filing

reference in such filing. --- EX-99.1 (EX-99.1) --- SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates – Achieved $21.0 million in OGSIVEO ® (nirogacestat) net product revenue in the first quarter – – Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors

View on SEC.gov

Browse all earnings releases →

Source: SEC EDGAR

accession 0001773427-24-000016

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.